save and improve the lives of patients
learn moreawareness
There is an outstanding need for new treatments for bladder cancer. We are proud to support the Bladder Cancer Advocacy Network in building awareness of the need for a cure.
results
Our preliminary Phase 3 data show Vicinium® is very well-tolerated and with demonstrated efficacy in patients with high-grade NMIBC.
innovation
Vicinium is a targeted fusion protein designed to overcome the fundamental efficacy and safety challenges inherent in existing antibody-drug conjugates.
bringing new hope for treating bladder cancer
Vicinium is our novel, lead product candidate that we hope will change the treatment landscape for patients with high-grade, non-muscle invasive bladder cancer (NMIBC). To-date, Vicinium has been well-tolerated in treated patients and has demonstrated efficacy, resulting in a 17% complete response rate for patients with 12-month follow-ups in our ongoing Phase 3 trial.
LEARN MORE
BLADDER CANCER
6th
most common cancer
72
average age of diagnosis
80,000+
new cases each year in the U.S.
$4 billion
annual costs
what we’ve been up to
09/03/19
Sesen Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference
08/26/19
Sesen Bio Announces CFO Transition as Company Drives Towards Anticipated Initiation of BLA Submission in 4Q 2019
08/08/19
Sesen Bio Reports Positive, Preliminary Data Update from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer
RENEW LIFE
change lives with us
We are a group of motivated individuals who are committed to changing lives for the better. Learn more about our open positions and how you can renew life with us.
learn more